Literature DB >> 19399792

The natural history of chronic hepatitis B virus infection.

Brian J McMahon1.   

Abstract

Chronic hepatitis B virus (HBV) infection has a complicated course. Three phases are identified: an immune tolerant phase with high HBV DNA and normal alanine aminotransferase (ALT) levels associated with minimal liver disease; an immune active phase with high HBV DNA and elevated ALT levels with active liver inflammation; and an inactive phase with HBV DNA levels < 2000 IU/mL and normal ALT levels with minimal inflammation and fibrosis on liver biopsy. Affected persons can move progressively from one phase to the next and may revert backward. The primary adverse outcomes of chronic HBV infection are hepatocellular carcinoma (HCC) and cirrhosis. Published natural history studies were reviewed and ranked by the strength of evidence regarding the study design. Factors with the highest evidence of risk for development of HCC or cirrhosis from population-based prospective cohort studies include male sex, family history of HCC, HBV DNA level above 2000 IU/mL in persons above age 40, HBV genotypes C and F, and basal core promoter mutation. Those with the next highest level of evidence include aflatoxin exposure, and heavy alcohol and tobacco use. Improved methods to identify persons at highest risk of developing HCC or cirrhosis are needed to allow intervention earlier with antiviral therapy in appropriate patients. Future studies should include prospective follow-up of established population-based cohorts as well as new cohorts recruited from multiple centers stratified by HBV genotypes/subgenotypes and clinical phase to determine the incidence of the various HBV phases, HCC, and cirrhosis. Also, nested case-control studies assessing immunological and host genetic factors among persons with active and inactive disease phases, HCC, and cirrhosis could be conducted using these types of cohorts.

Entities:  

Mesh:

Year:  2009        PMID: 19399792     DOI: 10.1002/hep.22898

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  239 in total

Review 1.  Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Understanding the natural history of chronic HBV and HCV infections.

Authors:  David L Thomas; Adrian M Di Bisceglie; Harvey J Alter; Norah A Terrault
Journal:  J Fam Pract       Date:  2010-04       Impact factor: 0.493

3.  Ethnic differences in prevalence and barriers of HBV screening and vaccination among Asian Americans.

Authors:  Carol Strong; Sunmin Lee; Miho Tanaka; Hee-Soon Juon
Journal:  J Community Health       Date:  2012-10

Review 4.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

5.  Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.

Authors:  Yanbing Zeng; Mingliang Luo; Jianlin Lin; Hanqing He; Xuan Deng; Shuyun Xie; Ya Fang
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

6.  Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.

Authors:  Andrés Duarte-Rojo; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

7.  Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy?

Authors:  Kali Zhou; Norah Terrault
Journal:  AME Med J       Date:  2018-02-10

8.  Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis.

Authors:  Aida Siyahian; Saad Ullah Malik; Adeela Mushtaq; Carol L Howe; Aneela Majeed; Tirdad Zangeneh; Samar Iftikhar; Shahid Habib; Umar Zahid; Irbaz Bin Riaz; Zabih Warraich; Warda Faridi; Faiz Anwer
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-12       Impact factor: 5.742

9.  Hepatitis B Virus-HIV Coinfection: Forgotten but Not Gone.

Authors:  Narayan Dharel; Richard K Sterling
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-12

Review 10.  Virus and Host Testing to Manage Chronic Hepatitis B.

Authors:  Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Henry Lik-Yuen Chan
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.